Plasminogen, human-tvmh (Ryplazim) was approved for medical use in the United States in June 2021. It is the first therapy for<unk>  approved by the U.S. Food and Drug Administration (FDA).
Hypoplasminogenemia
Hemosiderinuria
Aceruloplasminemia
Pentosuria
Pipecolic acidemia
Histidinemia
Galactosemia
Hyperphenylalaninemia